Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pandemic Influenza alphavaccine (H1B)
- Development stage
- Preclinical
- Lead developer
- AlphaVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Pandemic Influenza alphavaccine (H1B) is an investigational vaccine developed by AlphaVax using its proprietary viral replicon particle (VRP) technology. The platform utilizes an alphavirus vector, specifically derived from an attenuated strain of the Venezuelan Equine Encephalitis (VEE) virus. In this system, the structural genes of the VEE virus are replaced with the genetic sequence for H1B influenza antigens, creating a replication-defective particle. Upon administration, these VRPs infect host cells and express the target influenza antigens at high levels, but they are unable to produce new infectious virus particles. This mechanism is designed to trigger a robust and comprehensive immune response, including both neutralizing antibodies and cellular immunity, to provide protection against pandemic influenza strains associated with the H1B designation.
- Other names
- H1B influenza antigens-alphavaccineH-1B influenza antigens-alphavaccineH 1B influenza antigens-alphavaccineRNA particle vaccineVRP vaccinepandemic influenza H1B vaccineAlphaVax H1B alphavaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Pandemic Influenza alphavaccine (H1B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pandemic Influenza alphavaccine (H1B).